Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

S. Al-Batran(Krankenhaus Nordwest), Elke Jäger(Krankenhaus Nordwest), Stephan Probst(Klinikum Bielefeld), Akin Atmaca(Heidelberg University), Jan Stoehlmacher(University of Southern California), Rolf Mahlberg(Klinikum Mutterhaus der Borromäerinnen), Mark Sievert(Sanofi (Germany)), Claudia Pauligk(Goethe University Frankfurt), Volker Rethwisch(Klinikum Dortmund), Mary Ann Fritz, J. T. Hartmann(Heidelberg University), Michael Clemens(Klinikum Mutterhaus der Borromäerinnen), G. Seipelt, Ralf‐Dieter Hofheinz(University of Mannheim), Nils Homann(Fraunhofer Project Centre Wolfsburg)
Annals of Oncology
August 1, 2008
10.1093/annonc/mdn403
Cited by 281

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
|The Lancet Oncology|2009|960